| Revenues | 0 |
| Research and development expenses | -6.03M |
| Less participation by the Office of the Chief Scientist and other parties | |
| Research and development expenses, net | -5M |
| General and administrative expenses | -1.56M |
| Operating loss | -6.56M |
| Financial (expenses) income, net | |
| Net loss for the period | -6.32M |
| Basic and diluted net loss per share | -0.08 |
| Weighted average number of shares used in computing basic and diluted net loss per share | |